Brief: PDS Biotech Completes First Stage Enrollment In Checkpoint Inhibitor Refractory Arm Of Phase 2 Clinical Trial
15/12/2022 13:45
Dec 15 (Reuters) - PDS Biotechnology Corp PDSB.O :
* PDS BIOTECH COMPLETES FIRST STAGE OF ENROLLMENT IN
CHECKPOINT
INHIBITOR REFRACTORY ARM OF PHASE 2 CLINICAL TRIAL IN ADVANCED
HPV16 POSITIVE HEAD AND NECK CANCER
Source text for Eikon: ID:nGNX7s6fNh
Further company coverage: PDSB.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on PDS Biotechnology
See all newsPDS Biotechnology Corp reports results for the quarter ended September 30 - Earnings Summary
PDS Biotechnology Q3 net loss narrows on lower R&D costs
PDS Biotechnology Corp expected to post a loss of 10 cents a share - Earnings Preview
Brief: PDS Biotech Announces Initial Closing Of Up To $22.3 Mln PIPE Financing
Brief: Pds Biotechnology Corp - On Aug 6, Approved Reduction In Force To Align Expenses With Strategic Priorities - SEC Filing